Original ContributionAn assessment by the Statin Liver Safety Task Force: 2014 update
Section snippets
Update on 2006 Statin Safety Task Force report questions
Statins are the most common drugs used in treatment of hypercholesterolemia and among the most commonly used pharmaceuticals in clinical practice. As acknowledged by the hepatologist experts in the 2006 National Lipid Association Statin Safety Task Force Report, statins can increase liver-associated enzymes.6 Table 2 lists the questions and answers addressed by these hepatology experts in 2006 as well as the list of questions and answers from this 2014 Task Force. The following are six
2014 Questions
- 1.
Have any unexpected safety concerns arisen since the regulatory recommendation that liver enzymes need not be measured after initiating statin therapy?
ANSWER: No.
STRENGTH OF RECOMMENDATION: A (strong).
QUALITY OF EVIDENCE: Low.
EXPLANATION: The initial 2006 National Lipid Association Statin Safety Task Force Expert Liver Panel recommended that routine liver enzyme testing not be required.6 Subsequently, in 2012, the FDA issued a communication regarding “Important safety label changes to
Recommendations to clinicians
Table 1 provides clinicians a summary of Hy's law, which represents the constellation of liver blood abnormalities with the highest potential for liver toxicity (eg, DILI). Table 2 provides a summary of recommendations made by the 2006 and 2014 Liver Safety Panels. Table 3 provides clinicians an “at-a-glance” summary of illustrative diagnoses for the patient with elevated liver enzymes, with or without statin use. The intended utility of Table 3 is to emphasize that when a statin-treated
References (24)
- et al.
Features, diagnosis, and treatment of nonalcoholic fatty liver disease
Clin Gastroenterol Hepatol
(2012) - et al.
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
J Clin Lipidol
(2013) - et al.
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
Lancet
(2010) - et al.
Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study
J Hepatol
(2007) - et al.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print]
J Am Coll Cardiol
(2013) - et al.
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
BMJ
(2008) - et al.
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members Appointed to the Eighth Joint National Committee (JNC 8)
JAMA
(2014) - et al.
Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia
Circulation
(2011) - US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)...
- et al.
An assessment of statin safety by hepatologists
Am J Cardiol
(2006)
Drug-induced acute liver failure: results of a U.S. multicenter, prospective study
Hepatology
Cited by (183)
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
2024, European Journal of Internal MedicineComprehensive review of statin-intolerance and the practical application of Bempedoic Acid
2024, Journal of CardiologyCardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease
2023, Endocrinology and Metabolism Clinics of North AmericaCurrent and future options in cholesterol lowering treatments
2023, European Journal of Internal MedicineCurrent Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology
2023, Clinics in Liver Disease
Disclosures: In the past 12 months, Dr. Harold Bays has served as a consultant and/or speaker to Amarin, Amgen, Astra Zeneca, Bristol Meyers Squibb, Catabasis, Daiichi Sankyo, Eisai, Isis, Merck, Novartis, VIVUS, WPU, and his research site has received research grants from Alere, Amarin, Amgen, Ardea, Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, California Raisin Board, Catabasis, Eisai, Elcelyx, Eli Lilly, Esperion, Essentialis, Forest, Gilead, Given, GlaxoSmithKline, High Point Pharmaceuticals LLC, Hoffman LaRoche, Home Access, Janssen, Merck, Metabolex, Micropharma Limited, Necktar, Novartis, Novo Nordisk, Omthera, Orexigen, Pfizer, Pronova, Regeneron, Stratum Nutrition, Takeda, TIMI, Transtech Pharma, Trygg, VIVUS, WPU, and Xoma. Dr. David Cohen reports having received consulting fees from Merck, Aegerion, Dignity Sciences, Genzyme, and Novartis, and has additionally received honoraria from Merck. Dr. Naga Chalasani reports serving as a consultant to Aegerion, Salix, and Lilly; is on the Data and Safety Monitoring Boards of AbbVie and Merck; and his institution has received research grants from Gilead, Intercept, Cumberland, and Enterome. Dr. Stephen Harrison discloses he has received consulting fees/honoraria from Merck, Vertex, and the Chronic Liver Disease Foundation; consulting fees from Nimbus and Genentech; and honoraria from the American Association for Study of Liver Diseases.
Disclaimer: The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of San Antonio Military Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, Department of Defense or the U.S. Government.